Bosutinib (SKI-606) Licensed by Pfizer

Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively.

Price Stock Quantity  
USD 91 In stock
USD 70 In stock
USD 270 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Bosutinib (SKI-606) Chemical Structure

Bosutinib (SKI-606) Chemical Structure
Molecular Weight: 530.45

Validation & Quality Control

Customer Product Validation(3)

Quality Control & MSDS

Related Compound Libraries

Src Inhibitors with Unique Features

  • Most Potent Src Inhibitor

    Dasatinib Src, IC50=0.8 nM.

  • FDA-approved Src Inhibitor

    Dasatinib Approved by FDA for CML and Ph+ ALL.

  • Newest Src Inhibitor

    PP1 Potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.

  • Classic Src Inhibitor

    KX2-391 The first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

Product Information

  • Compare Src Inhibitors
    Compare Src Products
  • Research Area
  • Bosutinib (SKI-606) Mechanism
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively.
Targets Abl [2]
(Cell-free assay)
Src [1]
(Cell-free assay)
IC50 1 nM 1.2 nM
In vitro Bosutinib is selective for Src over non-Src family kinases with an IC50 of 1.2 nM, and potently inhibits Src-dependent cell proliferation with an IC50 of 100 nM. [1] Bosutinib significantly inhibits the proliferation of Bcr-Abl-positive leukemia cell lines KU812, K562, and MEG-01 but not Molt-4, HL-60, Ramos, and other leukemia cell lines, with IC50 of 5 nM, 20 nM and 20 nM, respectively, more potently than that of STI-571. Similar to STI-571, Bosutinib displays antiproliferative activity against the Abl-MLV-transformed fibroblasts with IC50 of 90 nM. Bosutinib ablates tyrosine phosphorylation of Bcr-Abl and STAT5 in CML cells and of v-Abl expressed in fibroblasts at the concentration of ~50 nM, 10-25 nM and 200 nM, respectively, leading to the Bcr-Abl downstream signaling inhibition of Lyn/Hck phosphorylation. [2] Although unable to inhibit the proliferation and survival of breast cancer cells, Bosutinib significantly decreases the motility and invasion of breast cancer cells with IC50 of ~250 nM, involved with an increase in cell-to-cell adhesion and membrane localization of β-catenin. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
NB7M2TObmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlixTWM2OD1yLkC4NlMyKCEQvF2=MlSxV2FPT0WU
SW756MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWfkdIR[UUN3ME2wMlE1ODJ2IDFOwG0>Mn;ZV2FPT0WU
CTV-1Mm\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2HZSGlEPTB;MD6xOlM6QCBizszNNUC2OW16W0GQR1XS
HSC-4NILVNIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmjqTWM2OD1yLkG3NVU5KCEQvF2=NVLkeVZ{W0GQR1XS
LAMA-84NGDzUVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NG\xSZRKSzVyPUCuNlg3PjRiIN88US=>MlnpV2FPT0WU
KU812MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlPhTWM2OD1yLkO0NFY5KCEQvF2=MWXTRW5ITVJ?
HCC1806MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVTKOItDUUN3ME2wMlM2OjF4IDFOwG0>M3fM[HNCVkeHUh?=
DOKMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmfvTWM2OD1yLkO3O|g3KCEQvF2=M3;YTXNCVkeHUh?=
NCI-H209M4HsNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEjzbYdKSzVyPUCuOFA5ODhiIN88US=>M{\4VHNCVkeHUh?=
EoL-1-cellM1nTcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWrIblZRUUN3ME2wMlQyPTd4IDFOwG0>M2joVXNCVkeHUh?=
H9NXOzOWYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkDBTWM2OD1yLkSzOFY1KCEQvF2=NVLzc2h5W0GQR1XS
EM-2MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUPJR|UxRTBwNEO4PUAh|ryPNFrIOnFUSU6JRWK=
NCI-H292MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2PRUGlEPTB;MD60OFExQCBizszNMW\TRW5ITVJ?
697MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGfDUVNKSzVyPUCuOFU3OzNiIN88US=>MWPTRW5ITVJ?
BHT-101NEHjUWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3TLSGlEPTB;MD60OlU6KCEQvF2=NFTFdY5USU6JRWK=
BE-13NX3RO3dsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV3LTGJnUUN3ME2wMlQ5PTd{IDFOwG0>M2fMR3NCVkeHUh?=
RS4-11NGPHe3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF22bIRKSzVyPUCuOFg2QDRiIN88US=>NXPBSZYxW0GQR1XS
IGROV-1M33Ge2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmSxTWM2OD1yLkS4O|k4KCEQvF2=NIqxT|NUSU6JRWK=
KE-37M3zPSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVu2cGl6UUN3ME2wMlQ6PTB7IDFOwG0>Mln1V2FPT0WU
BV-173NUTKc483T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXtS4F7UUN3ME2wMlUxPzl{IDFOwG0>NF7lW49USU6JRWK=
MEG-01MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVTJR|UxRTBwNUGyNVQhKM7:TR?=MYPTRW5ITVJ?
LB2241-RCCM{G0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYnJR|UxRTBwNUO3NVghKM7:TR?=NEGxNYtUSU6JRWK=
ACHNM{DYSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnroTWM2OD1yLkW0NFY6KCEQvF2=NV7NZnNQW0GQR1XS
CTB-1M1;LTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWnnR5hHUUN3ME2wMlU1QDJiIN88US=>NVjNOGRbW0GQR1XS
HT-1080M{Hhfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV3JR|UxRTBwNUWzOFkhKM7:TR?=M3;RO3NCVkeHUh?=
CHL-1NIDMNY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEK3e25KSzVyPUCuOVU1PjViIN88US=>NWjse3V4W0GQR1XS
EW-3M4\oN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTBwNUW5N|UhKM7:TR?=M1HkdXNCVkeHUh?=
ES1MmfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXHlb5hvUUN3ME2wMlY4PDl6IDFOwG0>MnjNV2FPT0WU
KASUMI-1NX3OO5VYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGTydlhKSzVyPUCuO|I{OyBizszNNIm4PGVUSU6JRWK=
SW13NI\OS2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTBwN{O3PVghKM7:TR?=MVjTRW5ITVJ?
A3-KAWMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M321bWlEPTB;MD63PVIxQCBizszNNF3ORVFUSU6JRWK=
LB771-HNCMnntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYrJR|UxRTBwOEOxNFQhKM7:TR?=NFTvUpZUSU6JRWK=
OC-314M{KyNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXrJR|UxRTBwOE[5OlUhKM7:TR?=MknqV2FPT0WU
MLMANI\NTXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYHJR|UxRTBwOUC2O|UhKM7:TR?=M{fxUXNCVkeHUh?=
KARPAS-45MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{D2SmlEPTB;MD65NlQ3PiBizszNNYn3dXpUW0GQR1XS
CAL-27Mm\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYLJR|UxRTBwOUK5NFYhKM7:TR?=M2DnRXNCVkeHUh?=
SK-NEP-1NHzRbZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYHqSnVQUUN3ME2wMlk4OjR6IDFOwG0>M1\pOXNCVkeHUh?=
COR-L105NV;MSmZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWrSTI14UUN3ME2xMlAxOzl2IDFOwG0>NGPqXndUSU6JRWK=
TI-73M2\QeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NICyTJZKSzVyPUGuNFE3PSBizszNNVzLdIZjW0GQR1XS
JVM-3MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlfsTWM2OD1zLkC1NFE4KCEQvF2=M3riVXNCVkeHUh?=
HAL-01M{H4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1PHcmlEPTB;MT6wPFgyKCEQvF2=MnLqV2FPT0WU
QIMR-WILMlXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkPXTWM2OD1zLkC5NFU5KCEQvF2=NEj4ZYlUSU6JRWK=
HSC-3NHLjRY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUPieoVoUUN3ME2xMlEyPzh|IDFOwG0>M3LKWHNCVkeHUh?=
KY821M{ToWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEC2fndKSzVyPUGuNVM{PTFiIN88US=>NGDJXZRUSU6JRWK=
5637MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3vOe2lEPTB;MT6xN|gxOyBizszNMX3TRW5ITVJ?
CAL-33NVHzRoNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXSw[WNHUUN3ME2xMlE6OzB{IDFOwG0>M1qxWHNCVkeHUh?=
ES4NYPBU5BtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkWyTWM2OD1zLkKwO|khKM7:TR?=NIm1fYFUSU6JRWK=
BHYNYTOR4hYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWXPN5JYUUN3ME2xMlIzQDl{IDFOwG0>NGTZN2tUSU6JRWK=
LB1047-RCCM2\FWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkWwTWM2OD1zLkKzO|g2KCEQvF2=MYXTRW5ITVJ?
H4NEe3fnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTFwMkSyOVUhKM7:TR?=M3X4T3NCVkeHUh?=
RPMI-8866MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{n1RWlEPTB;MT6yOlExPiBizszNNH3qdFJUSU6JRWK=
HO-1-N-1NITLSGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUXJR|UxRTFwMk[zOlkhKM7:TR?=MXrTRW5ITVJ?
BB30-HNCNUDJbFd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4fnS2lEPTB;MT6yPFcyPCBizszNNYL1UFJqW0GQR1XS
PC-14NX7NSJhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1TEXGlEPTB;MT6yPVIxPSBizszNMo\tV2FPT0WU
NUGC-3NIjyOYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2G4SWlEPTB;MT6yPVM2PiBizszNM2fURnNCVkeHUh?=
A4-FukM3LsTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3;qfGlEPTB;MT6zNFcxPCBizszNMWPTRW5ITVJ?
MHH-NB-11MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MknCTWM2OD1zLkOxN|g{KCEQvF2=MoTiV2FPT0WU
KOSC-2MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnPkTWM2OD1zLkOxO|c2KCEQvF2=NUjwSVhUW0GQR1XS
A498NV3UTFBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWTJR|UxRTFwNECxNVMhKM7:TR?=NES1[ItUSU6JRWK=
KG-1Mkm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYXMZ2lFUUN3ME2xMlQyOjd|IDFOwG0>NHXOZlhUSU6JRWK=
DELMlfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnvMTWM2OD1zLkSzOlU4KCEQvF2=MlrCV2FPT0WU
EW-16M4D4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV7JR|UxRTFwNEO5O|MhKM7:TR?=NIPwfmdUSU6JRWK=
BPH-1MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWXJR|UxRTFwNES4NFUhKM7:TR?=Ml3QV2FPT0WU
JARMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MknCTWM2OD1zLkS5N|YhKM7:TR?=NFraN3VUSU6JRWK=
J-RT3-T3-5MkG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{DDWmlEPTB;MT61NVczOiBizszNMYDTRW5ITVJ?
A375MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEX4SIJKSzVyPUGuOVE4PzJiIN88US=>MX;TRW5ITVJ?
SW954MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXfJR|UxRTFwNUWwNFchKM7:TR?=MoftV2FPT0WU
Ca9-22Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInKSHZKSzVyPUGuOVYzPiBizszNMUjTRW5ITVJ?
D-566MGMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFzpW5BKSzVyPUGuOVcyPTViIN88US=>M1e5Z3NCVkeHUh?=
SCC-15M{HyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGK2VJFKSzVyPUGuOlE5ODRiIN88US=>Mnq3V2FPT0WU
HD-MY-ZNXjsPG57T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4rPWWlEPTB;MT62N|U5PCBizszNMoXlV2FPT0WU
HT-1376NYWzPGVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH7zR3NKSzVyPUGuOlQ{PiBizszNNXHmOWRCW0GQR1XS
CAL-54NFLFUYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXXJR|UxRTFwNkW3NFkhKM7:TR?=MmPCV2FPT0WU
ONS-76NWSwblZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3XNUWlEPTB;MT62O|U2OSBizszNMVzTRW5ITVJ?
EFO-27NEXTU|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTFwNki5NkAh|ryPNUPSZ2J{W0GQR1XS
769-PNX7ueIkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFLHZWFKSzVyPUGuOlk2QTZiIN88US=>MoWwV2FPT0WU
MV-4-11M1n0[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH\q[lRKSzVyPUGuOlk5PTZiIN88US=>NIDsc|RUSU6JRWK=
NKM-1NF[wfYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml7YTWM2OD1zLkexPFAzKCEQvF2=NU\INI9nW0GQR1XS
LOXIMVIMnO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEPkXXdKSzVyPUGuO|Q2QTliIN88US=>M17PcHNCVkeHUh?=
KYSE-140NHjVTnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWT6[XBwUUN3ME2xMlc2PjV3IDFOwG0>M13Ee3NCVkeHUh?=
ES5MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYLJR|UxRTFwOE[3OFchKM7:TR?=NF7yU4NUSU6JRWK=
BB65-RCCMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2HwVWlEPTB;MT64PVg1QSBizszNMWfTRW5ITVJ?
HNM36wN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWHwVGdGUUN3ME2xMlg6QDd2IDFOwG0>NVLxb5FIW0GQR1XS
A101DMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{W5SGlEPTB;MT65N|YzQCBizszNM1XienNCVkeHUh?=
LoVoNGLzb25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHjicopKSzVyPUGuPVc3PzliIN88US=>NXLxTW5ZW0GQR1XS
NCI-H526M4jzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVfsSodnUUN3ME2xMlk6OzJ3IDFOwG0>M2iwT3NCVkeHUh?=
NCI-H1693NVThN3VQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYXZXolTUUN3ME2xMlk6QDh6IDFOwG0>M2LvWnNCVkeHUh?=
OVCAR-4NV\kR3JFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml\3TWM2OD1{LkCwOFM2KCEQvF2=NF[2SFhUSU6JRWK=
SK-HEP-1NWLJSmF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYHJR|UxRTJwMEC3OFUhKM7:TR?=Mk\zV2FPT0WU
C2BBe1MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2fHVWlEPTB;Mj6wN|M4OiBizszNNVPIfJJUW0GQR1XS
MEL-JUSONFrGeoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIjoZ3NKSzVyPUKuNFQ1PjRiIN88US=>M3m3PXNCVkeHUh?=
MOLT-16NEWxcpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlSyTWM2OD1{LkC3NFU5KCEQvF2=MYLTRW5ITVJ?
NBsusSRNEjWbplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXXJR|UxRTJwMEm4PFkhKM7:TR?=NE\JXVRUSU6JRWK=
TK10M1nY[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3\OV2lEPTB;Mj6xN|Q2QCBizszNNFP6ZlVUSU6JRWK=
CAL-39NFqydolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmnFTWM2OD1{LkG0OFghKM7:TR?=NF7KSGRUSU6JRWK=
NCI-H2030NYTsXZRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4\vcmlEPTB;Mj6xPFk4OyBizszNM3rw[XNCVkeHUh?=
HCT-116M3nVW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTJwMkK5PFQhKM7:TR?=M37CfXNCVkeHUh?=
HTC-C3MlXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1jlXWlEPTB;Mj6yOlgzPCBizszNNFfCdIZUSU6JRWK=
TYK-nuMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2nacGlEPTB;Mj6zNFkxQSBizszNM2frUXNCVkeHUh?=
FADUMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3TnVGlEPTB;Mj6zNlI6PiBizszNNV70Uo01W0GQR1XS
A431NFz4PZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4e4fmlEPTB;Mj6zO|AzPSBizszNNXr4Tnc2W0GQR1XS
TE-11NELkW2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4XtVWlEPTB;Mj6zPFAyQSBizszNMlr3V2FPT0WU
CAL-12TMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1X1bGlEPTB;Mj60NFQyPyBizszNMVrTRW5ITVJ?
DBNEXCVnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIPJXYpKSzVyPUKuOFI5PjliIN88US=>NF73S4FUSU6JRWK=
L-363Mnj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTJwNEO1NFchKM7:TR?=M{nTR3NCVkeHUh?=
MSTO-211HNYPRTlJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVjJR|UxRTJwNk[zPVEhKM7:TR?=M4Xv[3NCVkeHUh?=
SK-UT-1Mnn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUfNcpBmUUN3ME2yMlcyPDB4IDFOwG0>MYHTRW5ITVJ?
RPMI-8226MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVTJR|UxRTJwN{OxOlQhKM7:TR?=NVmydlYyW0GQR1XS
SF295M2D2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFiyUJdKSzVyPUKuO|Q{OSBizszNNUO4S5dkW0GQR1XS
OS-RC-2M33qTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3T3WmlEPTB;Mj63OlY4OyBizszNMYDTRW5ITVJ?
SK-MEL-24Mn\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NILxWI1KSzVyPUKuO|gzOjRiIN88US=>MV7TRW5ITVJ?
COR-L23Mnj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIPyXGNKSzVyPUKuO|k1PjRiIN88US=>NWP5[2pKW0GQR1XS
MHH-PREB-1MnnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml35TWM2OD1{LkiwNVYyKCEQvF2=NUXvU2N7W0GQR1XS
SK-N-DZM1rxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4LlRmlEPTB;Mj64NVY{QCBizszNNIG4XIJUSU6JRWK=
OMC-1M{Tvd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVfNRWltUUN3ME2yMlg2ODB|IDFOwG0>MYTTRW5ITVJ?
SK-MEL-2M1OyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkCzTWM2OD1{Lki5NlQ{KCEQvF2=MVTTRW5ITVJ?
SASMlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnrITWM2OD1{Lkm5OFE2KCEQvF2=MY\TRW5ITVJ?
EPLC-272HNIK1PIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NG[zSlFKSzVyPUOuNFAzOzViIN88US=>MXnTRW5ITVJ?
8505CMkjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUjYOYQxUUN3ME2zMlExOzBzIDFOwG0>NWr0[3RVW0GQR1XS
EW-11NIrPOZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\yZXBEUUN3ME2zMlE1Ojd5IDFOwG0>NIDZSndUSU6JRWK=
YKG-1MoLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIn3PI5KSzVyPUOuNVQ4ODZiIN88US=>MXTTRW5ITVJ?
EC-GI-10NIDtUpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVX6[G5OUUN3ME2zMlE4OjZ|IDFOwG0>M2DGWXNCVkeHUh?=
SK-LU-1M4n6TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYe5T5M{UUN3ME2zMlE5PDF6IDFOwG0>NEfLelRUSU6JRWK=
P30-OHKM2HIR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWD6T2l3UUN3ME2zMlIxOTF5IDFOwG0>M4\hZnNCVkeHUh?=
T-24M{nNOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYLQVmFjUUN3ME2zMlIyQDF2IDFOwG0>Mo\kV2FPT0WU
HSC-2NFSxfpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV3wV|dEUUN3ME2zMlIzOjN{IDFOwG0>M3LLR3NCVkeHUh?=
SK-MES-1MofyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmjhTWM2OD1|LkK0PFI6KCEQvF2=MUHTRW5ITVJ?
SW48M{PMdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVzjOmZjUUN3ME2zMlI2PDh4IDFOwG0>NUPScXJTW0GQR1XS
ME-180M4HrOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXLJR|UxRTNwMk[wOVEhKM7:TR?=M13hbXNCVkeHUh?=
NCI-H2009M4\N[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnXITWM2OD1|LkK5NFEhKM7:TR?=NYjWbms6W0GQR1XS
HL-60MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M33PPWlEPTB;Mz6yPVE{KCEQvF2=MnvVV2FPT0WU
NCI-N87MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYDjSmlIUUN3ME2zMlMxOTd{IDFOwG0>M{jiR3NCVkeHUh?=
GMS-10MnPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2SwUmlEPTB;Mz6zOFA5PiBizszNNGrCWHFUSU6JRWK=
SCHNI[zUXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTNwNEC4OFQhKM7:TR?=NUfFW3o5W0GQR1XS
C-33-AMlnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUnJOIpuUUN3ME2zMlQyPDJzIDFOwG0>M2nTRnNCVkeHUh?=
NCI-H1703M3P5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVnLdY9xUUN3ME2zMlQyQDF{IDFOwG0>M17hXHNCVkeHUh?=
A427NVPjOG1PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWLJR|UxRTNwNE[xNlQhKM7:TR?=MnnSV2FPT0WU
MOLT-4NWfTemQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4TY[mlEPTB;Mz60PFE6QSBizszNMUjTRW5ITVJ?
NCI-H1792NHn4W3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml3wTWM2OD1|LkS5PFAzKCEQvF2=MmfmV2FPT0WU
NCI-H1650NXzWOHJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmDZTWM2OD1|LkW3NlkhKM7:TR?=NG\1bHFUSU6JRWK=
H-EMC-SSNWHVe4VjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXTJR|UxRTNwNUi1OlkhKM7:TR?=NYLwPZRxW0GQR1XS
SW982MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHX1dFJKSzVyPUOuOVg5OjliIN88US=>M1HZdnNCVkeHUh?=
DSH1NEHZfpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3jvR2lEPTB;Mz62OFEzOiBizszNMWfTRW5ITVJ?
NOS-1NWO1W4htT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn;uTWM2OD1|Lk[0Nlc3KCEQvF2=NE[yc3hUSU6JRWK=
BT-549MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHfwZldKSzVyPUOuOlc5PTRiIN88US=>NIPSPYdUSU6JRWK=
HuCCT1Mmr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV3QWFFPUUN3ME2zMlc1OTd5IDFOwG0>MoHpV2FPT0WU
NCI-H1755M363e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVLJR|UxRTNwOU[5O|EhKM7:TR?=MljRV2FPT0WU
KYSE-450M{\mT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFXaSJFKSzVyPUOuPVY6QTdiIN88US=>NYWzW4RwW0GQR1XS
MIA-PaCa-2NV7L[5l{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHvnfldKSzVyPUOuPVczQSBizszNNU\UVGJHW0GQR1XS
U-266MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoPJTWM2OD1|Lkm3OFgyKCEQvF2=M3XwTnNCVkeHUh?=
MewoNXi2d2dpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXPwRmF2UUN3ME20MlA3OzZzIDFOwG0>NInRbmhUSU6JRWK=
KYSE-520NFjBUGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MljqTWM2OD12LkC5O|k6KCEQvF2=NFnvcVJUSU6JRWK=
MN-60M3G5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFXtRWtKSzVyPUSuNVA2ODFiIN88US=>NXT1O|c2W0GQR1XS
Ramos-2G6-4C10M3i3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3nsW2lEPTB;ND6xOlc{QSBizszNM4XjS3NCVkeHUh?=
SK-MEL-1M{Pne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUnmRW06UUN3ME20MlE5Pjl3IDFOwG0>M2f6XXNCVkeHUh?=
ABC-1M{HnWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{fzXmlEPTB;ND6yN|M{OyBizszNMXvTRW5ITVJ?
CAKI-1M4qycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3zNUmlEPTB;ND6yOFU4OSBizszNNXLUWHF[W0GQR1XS
HOSNG\LeoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXS3OWJkUUN3ME20MlI6OTRzIDFOwG0>M3zhN3NCVkeHUh?=
SN12CMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTRwM{SyOFQhKM7:TR?=NGPad2xUSU6JRWK=
NB13MnHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH3HVYVKSzVyPUSuN|c{PTViIN88US=>NUXROIU{W0GQR1XS
M14NYLvR2tXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXsXJFrUUN3ME20MlQ5Pzl{IDFOwG0>NXLrbXM2W0GQR1XS
GP5dNFjhWVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3y3UGlEPTB;ND61NFEzKCEQvF2=NGiyPVNUSU6JRWK=
NCI-H720NWXDVVRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2K5UmlEPTB;ND61N|YyOiBizszNM{H5S3NCVkeHUh?=
D-423MGM{n5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVzIdmRCUUN3ME20MlU{QTJ2IDFOwG0>NFPoPJdUSU6JRWK=
ChaGo-K-1MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlnOTWM2OD12LkW5OVU6KCEQvF2=NXPhZ2FFW0GQR1XS
MEL-HOMmPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVHJR|UxRTRwNkGyOlEhKM7:TR?=MlzvV2FPT0WU
MHH-ES-1NVPuUJJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGXIXG5KSzVyPUSuOlI1OTFiIN88US=>MnzmV2FPT0WU
KYSE-270NXr2dmlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{fkb2lEPTB;ND62OVEzPiBizszNNEH0TJVUSU6JRWK=
GI-ME-NNWjk[Wg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2LWN2lEPTB;ND63NVI6OSBizszNMXnTRW5ITVJ?
HOP-92Mm\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2LlcGlEPTB;ND64NVM4QSBizszNMmi0V2FPT0WU
MKN1MkT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYjoUXBGUUN3ME20Mlg{QTF2IDFOwG0>NIPtWFdUSU6JRWK=
ML-2MlrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEi0VoZKSzVyPUSuPFU3OjZiIN88US=>NWe1dHd[W0GQR1XS
RO82-W-1M{jyXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV\JR|UxRTRwOUK5PEAh|ryPNVPMWY1kW0GQR1XS
G-361NUDBc4k5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mln0TWM2OD13LkCxNFA{KCEQvF2=NFHzcFJUSU6JRWK=
HC-1NGLuTZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3fuOWlEPTB;NT6wN|I6OSBizszNNX;T[mdRW0GQR1XS
EW-24NWr3UHlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlvpTWM2OD13LkC0NFM5KCEQvF2=Ml34V2FPT0WU
HuP-T4NUfGfZp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml2yTWM2OD13LkG0N|M1KCEQvF2=M3j0R3NCVkeHUh?=
8-MG-BAM4nZd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUixe2lnUUN3ME21MlM1OjhiIN88US=>MYLTRW5ITVJ?
HGC-27NFnL[4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVzJR|UxRTVwM{e2PFIhKM7:TR?=MlzyV2FPT0WU
TE-12NF\vRVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NI\tV|hKSzVyPUWuOFE2QDViIN88US=>M4[zRnNCVkeHUh?=
GT3TKBM2rRSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk[2TWM2OD13LkS0NlEzKCEQvF2=M3HVenNCVkeHUh?=
DOHH-2M{TDRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUPFbFR{UUN3ME21MlQ2QTh4IDFOwG0>MYDTRW5ITVJ?
Ca-SkiMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWTJR|UxRTVwNE[xNVUhKM7:TR?=NVHl[YR{W0GQR1XS
A172NYOxVW9uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTVwNUS5NlUhKM7:TR?=M{TLN3NCVkeHUh?=
EGI-1NH7BcJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4DYOWlEPTB;NT61PFk{QCBizszNMkHFV2FPT0WU
MZ2-MELNELqe|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlLZTWM2OD13Lk[xOFg3KCEQvF2=NF7jdFVUSU6JRWK=
SW1710MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGrFZlZKSzVyPUWuOlkxQTFiIN88US=>NYPIVFlsW0GQR1XS
HT-144MoToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmHFTWM2OD13LkeyOlg2KCEQvF2=MUjTRW5ITVJ?
PA-1MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{j6emlEPTB;NT64NVg6OyBizszNMV7TRW5ITVJ?
HCC1937M1WyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFnBZmJKSzVyPUWuPFM6OjliIN88US=>MkHBV2FPT0WU
SK-OV-3NXzqbm9VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLJR|UxRTVwOUGxNlEhKM7:TR?=NEnkdFFUSU6JRWK=
K5NYftOXBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3nlZWlEPTB;Nj6wOVE4KCEQvF2=NUTGTYUzW0GQR1XS
NMC-G1MoP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTZwMEe3PVchKM7:TR?=MU\TRW5ITVJ?
MDA-MB-361MoHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF;jZo5KSzVyPU[uNFkzPjFiIN88US=>NG\meHFUSU6JRWK=
EKVXMl\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkWwTWM2OD14LkGzOVAyKCEQvF2=Ml62V2FPT0WU
ES7MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlPiTWM2OD14LkG2NVE2KCEQvF2=Moj3V2FPT0WU
KS-1M{nUSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoXDTWM2OD14LkG3PVk{KCEQvF2=MUjTRW5ITVJ?
NCI-H661NIqwfWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2PDZmlEPTB;Nj6xPFA5OSBizszNNXvMbXZEW0GQR1XS
ES8MnyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4G5V2lEPTB;Nj6xPFA5OiBizszNMnfwV2FPT0WU
NCI-H23MmrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1TnbWlEPTB;Nj6yNVgyPiBizszNNFvRSlZUSU6JRWK=
T47DMlvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoXWTWM2OD14LkK2OFU4KCEQvF2=MkjyV2FPT0WU
A2780M1LGZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3PIfmlEPTB;Nj6zO|cxOSBizszNNWHxSWlEW0GQR1XS
SCC-4NVjFbo02T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYrDcFNjUUN3ME22MlQ{PTZzIDFOwG0>Mn[yV2FPT0WU
VA-ES-BJM3K3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVr4PJl3UUN3ME22Mlk4ODR|IDFOwG0>M1TaSnNCVkeHUh?=
no-11NGryWYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkXKTWM2OD15LkG2OFEhKM7:TR?=Ml3EV2FPT0WU
KU-19-19M2W2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkSyTWM2OD15LkG2OFc3KCEQvF2=MkDNV2FPT0WU
MKN45MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2C0bmlEPTB;Nz6xPFY6QSBizszNMlTzV2FPT0WU
SCC-25NYmyb5l7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mo\wTWM2OD15LkKzOFE1KCEQvF2=M1rONHNCVkeHUh?=
ETK-1NUHmfZlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NECzT5BKSzVyPUeuNlU2OTRiIN88US=>NHrCVJBUSU6JRWK=
COR-L88NGW2U2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFLmNJNKSzVyPUeuNlk{OTliIN88US=>NHT4U3ZUSU6JRWK=
8305CNE[5Z45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWjJR|UxRTdwM{K0PVIhKM7:TR?=MV\TRW5ITVJ?
Detroit562NFvwRndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXLJR|UxRTdwM{K1NFYhKM7:TR?=NGC4OWJUSU6JRWK=
SNU-449MlHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmfvTWM2OD15LkO3OlUyKCEQvF2=Mn2yV2FPT0WU
A704M4nSXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYmwSHlwUUN3ME23MlM5Ojd6IDFOwG0>M2foTnNCVkeHUh?=
D-502MGMlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUXGZlR1UUN3ME23MlM5PDd|IDFOwG0>MnTJV2FPT0WU
NCI-H2228Ml7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVHYV4ljUUN3ME23MlQyPDV6IDFOwG0>MkC4V2FPT0WU
CHP-212M4Ph[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHXQZm9KSzVyPUeuOVE5QTZiIN88US=>NG\zfXlUSU6JRWK=
VMRC-RCZNX74U|lxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXz5Noc5UUN3ME23MlU6ODZ4IDFOwG0>MmGzV2FPT0WU
RPMI-2650MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{PzPGlEPTB;Nz63NFMyOiBizszNMXXTRW5ITVJ?
HCC2218M3v4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXfJR|UxRTdwN{KyOVghKM7:TR?=M3TIXHNCVkeHUh?=
GCTM1ywc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXHP[ZNFUUN3ME23MlgzOTd{IDFOwG0>NXX2Z4NwW0GQR1XS
SW780MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUexUHZvUUN3ME23Mlk6ODZiIN88US=>MoL4V2FPT0WU
KMOE-2M3zMdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoGwTWM2OD16LkC0NFchKM7:TR?=MlXtV2FPT0WU
KYSE-180MorjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGjYVGJKSzVyPUiuNFg3PDhiIN88US=>NVrQZ|ZSW0GQR1XS
TE-1NHq3VVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoXXTWM2OD16LkGxNFU4KCEQvF2=MWLTRW5ITVJ?
OAW-42MlTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVzJR|UxRThwMkW0PVYhKM7:TR?=MULTRW5ITVJ?
VM-CUB-1M2fybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4DaVGlEPTB;OD6yPFM3PCBizszNMle4V2FPT0WU
ECC10NX\zeIppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1qxRmlEPTB;OD6yPFM6PyBizszNMmnDV2FPT0WU
SW1573NV\lT2FIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXvJ[JVbUUN3ME24MlQ1PDZ3IDFOwG0>NUnIVWxkW0GQR1XS
NCI-H1299MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1u5eWlEPTB;OD61PVc4PCBizszNM1PJNHNCVkeHUh?=
ALL-PONHj0e|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXvOZ|JqUUN3ME24MlY3PTl5IDFOwG0>MlLNV2FPT0WU
OVCAR-5NWTzPW5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVzJR|UxRThwN{e2NlUhKM7:TR?=M2WwdXNCVkeHUh?=
NCI-SNU-5MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXLJfFVMUUN3ME24Mlg{ODBzIDFOwG0>MWDTRW5ITVJ?
NCI-H2342MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mnu5TWM2OD16LkizNVAyKCEQvF2=M2XvUHNCVkeHUh?=
RPMI-7951MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYLJR|UxRThwOESxOVchKM7:TR?=M2DidHNCVkeHUh?=
RCM-1MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlvsTWM2OD17LkC4NVQ2KCEQvF2=MVfTRW5ITVJ?
DaoyNYPKRZVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVi5eYkxUUN3ME25MlEzODJ6IDFOwG0>M2H0dXNCVkeHUh?=
HCC1395NITpVmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2j4WmlEPTB;OT6zNFg6PiBizszNMYPTRW5ITVJ?
786-0NV;QeGRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRTlwM{[wNlYhKM7:TR?=M33OOXNCVkeHUh?=
GAMGNF3udplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlTPTWM2OD17Lk[1OVM1KCEQvF2=MVjTRW5ITVJ?
HCC1954M1TYeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXvpZVBwUUN3ME25Mlg2QDV7IDFOwG0>NXvNS284W0GQR1XS
NCI-H1838MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV\xNHdxUUN3ME25MlkxOzdzIDFOwG0>M1L3[HNCVkeHUh?=
SW620M{DmV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2nrbGlEPTB;OT65OVM2PyBizszNMoDwV2FPT0WU
NCI-H358NIi5bHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEDBRXFKSzVyPUGwMlQyQTdiIN88US=>M4fydnNCVkeHUh?=
NCI-H1793NF7QU3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGraXYxKSzVyPUGwMlQzPDhiIN88US=>MUnTRW5ITVJ?
NCI-H1666NIDiZZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXP5TY9KUUN3ME2xNE41OzV3IDFOwG0>MkHZV2FPT0WU
MZ7-melNGTIfphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3PtUGlEPTB;MUCuOFc2OyBizszNNVu1WGMxW0GQR1XS
MDA-MB-175-VIINF65fWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmrmTWM2OD1zMD62N|k3KCEQvF2=M{n2UXNCVkeHUh?=
COLO-829NV\2OFdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGPT[FJKSzVyPUGwMlgxODRiIN88US=>M33aNHNCVkeHUh?=
RVH-421NGHaTJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHPwNGFKSzVyPUGxMlE2OiBizszNM4\xWnNCVkeHUh?=
A549MoWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV3JR|UxRTFzLkK0O|ghKM7:TR?=M{HY[3NCVkeHUh?=
DJM-1NEfVe3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX\Wb41vUUN3ME2xNU4{QDN|IDFOwG0>MXLTRW5ITVJ?
IST-MEL1M4joTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX7BbGZZUUN3ME2xNU44OzF7IDFOwG0>MX;TRW5ITVJ?
BENMnO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkSyTWM2OD1zMT63OFAzKCEQvF2=M1rFW3NCVkeHUh?=
KM12MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUPn[ZQ3UUN3ME2xNU46ODlzIDFOwG0>M1rPOHNCVkeHUh?=
HuO9NE\tUnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmLrTWM2OD1zMj6wOlY3KCEQvF2=NIXnfJBUSU6JRWK=
U-2-OSNXKzfXYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoHNTWM2OD1zMj6wPFk{KCEQvF2=Ml\QV2FPT0WU
RH-1MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHXrXHNKSzVyPUGyMlQ1PzJiIN88US=>MWHTRW5ITVJ?
NCI-H1048NYHIXZRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIe5[WpKSzVyPUGyMlU2ODZiIN88US=>NGTySpdUSU6JRWK=
Mo-TNFTR[GtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk\xTWM2OD1zMj63N|A4KCEQvF2=M{HRbXNCVkeHUh?=
KYSE-150NVrpT5A4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3[zbGlEPTB;MUKuO|Q2PSBizszNNH;lT3JUSU6JRWK=
A388MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmXWTWM2OD1zMj63O|E{KCEQvF2=Mnf1V2FPT0WU
NCI-SNU-1NHXSTlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX\JR|UxRTF{LkiwOFYhKM7:TR?=MkHhV2FPT0WU
HELMlzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1;LemlEPTB;MUKuPFIyOiBizszNNXjnN3ZKW0GQR1XS
UM-UC-3NGfRSnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWnJR|UxRTF{Lki4O|QhKM7:TR?=NIXsTHBUSU6JRWK=
TGBC24TKBMnXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHLqRmlKSzVyPUGzMlAzPjdiIN88US=>NXvN[Gg{W0GQR1XS
SW626M{SydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlfkTWM2OD1zMz6yOFg2KCEQvF2=MV3TRW5ITVJ?
ES6MlTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NE[yOG1KSzVyPUGzMlI2OTJiIN88US=>MVvTRW5ITVJ?
NCI-H2029MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVX0SHpSUUN3ME2xN{45OTB6IDFOwG0>MVzTRW5ITVJ?
RXF393M4XpNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXrRWWh4UUN3ME2xN{46QTJ5IDFOwG0>NYrEOFk4W0GQR1XS
HMV-IINWW0WngxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV;aXZJ2UUN3ME2xOE4xPzhiIN88US=>NFTZeJFUSU6JRWK=
EW-22NXXNTm0xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{[wPWlEPTB;MUSuNVUxOiBizszNNHHyfYtUSU6JRWK=
AsPC-1M33sRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{PaO2lEPTB;MUSuOVY1KCEQvF2=MlfLV2FPT0WU
COLO-678MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{PiXmlEPTB;MUSuO|I4OSBizszNNGjUSHZUSU6JRWK=
HCT-15M1ToXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MljSTWM2OD1zND64PFU2KCEQvF2=M{i1R3NCVkeHUh?=
HCE-TMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIjqNnNKSzVyPUG0Mlg5PzRiIN88US=>Mkj2V2FPT0WU
SF539MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MojKTWM2OD1zNT6wOlQ{KCEQvF2=M3nWNXNCVkeHUh?=
AU565NGO1UZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRTF3LkKwPVYhKM7:TR?=NIq5WZBUSU6JRWK=
JVM-2NVrOPIJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1jsVWlEPTB;MUWuNlY5OSBizszNM2XwdXNCVkeHUh?=
CaR-1Mn7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{HuZ2lEPTB;MUWuOFQyOiBizszNM2\te3NCVkeHUh?=
23132-87NWPBWmxYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1fxXmlEPTB;MUWuPFQ6PSBizszNNVfMTGVEW0GQR1XS
A673M4H5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTF3Lkm2N|YhKM7:TR?=M{fObHNCVkeHUh?=
KYSE-410MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2rNW2lEPTB;MU[uNFI6KCEQvF2=NV3meFRyW0GQR1XS
TE-9MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYG5[HlmUUN3ME2xOk4xPjJiIN88US=>NITwZ5VUSU6JRWK=
LU-139MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVvtXld7UUN3ME2xOk4yQDJ|IDFOwG0>MkfxV2FPT0WU
GCIYNFLX[YRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVy5NZRvUUN3ME2xOk4yQTF4IDFOwG0>NH35PFdUSU6JRWK=
JEG-3Mm\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFG0PXRKSzVyPUG2MlI2KCEQvF2=M3XZVnNCVkeHUh?=
RT-112NWDpXYRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYT5fJRXUUN3ME2xOk41OTR|IDFOwG0>NGXPe4NUSU6JRWK=
COLO-680NNWTTUGt4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1jDWWlEPTB;MU[uOVExQCBizszNNWrVWIpVW0GQR1XS
LU-134-AMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{HWemlEPTB;MU[uPVg6OyBizszNNI\BbFNUSU6JRWK=
MFM-223MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTF5LkG1N|UhKM7:TR?=NVO2THE2W0GQR1XS
SF126NHPnPY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXjJR|UxRTF5LkG3NFEhKM7:TR?=NIrJVnpUSU6JRWK=
NCI-H28NXr2N4ZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NELXVmhKSzVyPUG3MlIxPjZiIN88US=>NXvPOYl1W0GQR1XS
BFTC-905NULQb25KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVfJR|UxRTF5LkS4N|IhKM7:TR?=MXHTRW5ITVJ?
SCC-9Mo\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmnrTWM2OD1zNz62Nlg2KCEQvF2=M3nBdHNCVkeHUh?=
KNS-62NVHvdow4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXvyd3pjUUN3ME2xO{43PjJ7IDFOwG0>NIDKeoJUSU6JRWK=
Hs-578-TMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{f2b2lEPTB;MUeuPFE1QSBizszNNInGNXBUSU6JRWK=
D-336MGMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn3NTWM2OD1zNz64Nlk1KCEQvF2=NYLkZZl6W0GQR1XS
NCI-H82MkHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NITpTIRKSzVyPUG4MlAyQDNiIN88US=>NHvIdmhUSU6JRWK=
EFM-19NHX3[oVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4OwU2lEPTB;MUiuNFU4PyBizszNNG[wN5NUSU6JRWK=
TGBC11TKBM1TYbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF;hPWRKSzVyPUG4MlExOjFiIN88US=>NVnUOVJWW0GQR1XS
HEC-1M{\sUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXPXUlA5UUN3ME2xPE4zQTF6IDFOwG0>MV;TRW5ITVJ?
HuP-T3M3S5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGX4bplKSzVyPUG4MlU6OjliIN88US=>NYLRZmc4W0GQR1XS
SF268NXjoZ|NOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHXhSoRKSzVyPUG4MlY4ODJiIN88US=>M1f0N3NCVkeHUh?=
COLO-792M2DIbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEPweoFKSzVyPUG4Mlc6QTdiIN88US=>MV\TRW5ITVJ?
HLEMlfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NG\UbVVKSzVyPUG4Mlg{OzFiIN88US=>NE\BbIxUSU6JRWK=
A204MmLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFTmU3JKSzVyPUG4MlkyPjRiIN88US=>NUW4TpVEW0GQR1XS
CAL-72MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3fQ[2lEPTB;MUmuNFg4PyBizszNMVzTRW5ITVJ?
U031NIHEc|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFPsTZFKSzVyPUG5MlQ6ODliIN88US=>NIX3NGRUSU6JRWK=
FTC-133MnfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTF7LkmzNFQhKM7:TR?=MXzTRW5ITVJ?
SK-MEL-28M4PGRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1nR[mlEPTB;MkCuN|c3OSBizszNM4rCenNCVkeHUh?=
KGNNHrjVmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXjCZmhqUUN3ME2yNE41Pjl7IDFOwG0>MXPTRW5ITVJ?
HCC2998MmXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVTYS4pZUUN3ME2yNU4{QTJ4IDFOwG0>NHvNflVUSU6JRWK=
GOTONVzmdZY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYPUOGJ5UUN3ME2yNU41QDViIN88US=>MnrxV2FPT0WU
AGSMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVHJR|UxRTJzLki0OVEhKM7:TR?=M4HZWHNCVkeHUh?=
EW-13MmDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{PTRmlEPTB;MkKuNVAzOiBizszNM1v5VXNCVkeHUh?=
P12-ICHIKAWAMmDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3nVbGlEPTB;MkKuNVYxOyBizszNMUDTRW5ITVJ?
NCI-H1395MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1;GdWlEPTB;MkKuNlkxPyBizszNNUW3dIpGW0GQR1XS
A2058MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{Phd2lEPTB;MkKuOFM1KCEQvF2=NGTt[nFUSU6JRWK=
SH-4M2fTOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M33nc2lEPTB;MkKuO|A1PSBizszNNIjL[JpUSU6JRWK=
DoTc2-4510NXfLZXY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnq2TWM2OD1{Mz62OFczKCEQvF2=NGPYXFNUSU6JRWK=
MMAC-SFMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV\oeppXUUN3ME2yN{43QTFzIDFOwG0>MVvTRW5ITVJ?
NCI-H510AM1fPPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEPFWVhKSzVyPUKzMlc6OzliIN88US=>M1TVOXNCVkeHUh?=
HDLM-2NYnpSldzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXH4NnBYUUN3ME2yOE4yPDZiIN88US=>NUWxeIhwW0GQR1XS
KINGS-1M17tZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVrOPWhvUUN3ME2yOE4zPDJiIN88US=>NVTE[oJVW0GQR1XS
NCI-H1648M1zhN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHTKTXlKSzVyPUK0MlQxOjRiIN88US=>Mn7nV2FPT0WU
HCC1187M3PVfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3fUO2lEPTB;MkWuNFI{PSBizszNNYTQOIVVW0GQR1XS
BALL-1NYTPVlRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVjIOnBCUUN3ME2yOU4zODZ{IDFOwG0>NXrjb3Y2W0GQR1XS
SBC-1MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVzJR|UxRTJ3LkK5PVMhKM7:TR?=MYTTRW5ITVJ?
BFTC-909Mk\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIq1PW9KSzVyPUK1MlM2PTFiIN88US=>MnTvV2FPT0WU
MOLT-13MnrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYrndHZOUUN3ME2yOU43PzR2IDFOwG0>NFjCT|lUSU6JRWK=
SW1990NFTKOGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2\ibGlEPTB;MkWuPVY2PSBizszNM2LtSXNCVkeHUh?=
DK-MGMYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGKxelhKSzVyPUK2MlA1PDNiIN88US=>MYjTRW5ITVJ?
TE-8MnfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYrJR|UxRTJ4LkC2OlghKM7:TR?=NVfNU5VCW0GQR1XS
BeckerNIDXSldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{\2bGlEPTB;Mk[uNVU4PCBizszNNXfNNFZ1W0GQR1XS
KYSE-70MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmnVTWM2OD1{Nj61N|E4KCEQvF2=NXfXT3h{W0GQR1XS
MKN7Mli2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVXWVJVzUUN3ME2yO{44PDd7IDFOwG0>NWTRWI5iW0GQR1XS
D-392MGMljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mlj6TWM2OD1{Nz63Olk1KCEQvF2=NHXlUZlUSU6JRWK=
NH-12NWXQdnlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1TBUGlEPTB;MkiuNVIzQSBizszNMVzTRW5ITVJ?
EW-18NIHNN25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTJ6LkKyNVghKM7:TR?=Mk\6V2FPT0WU
LCLC-97TM1NHv1W|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYjJR|UxRTJ6LkK3OlIhKM7:TR?=NHLBOJlUSU6JRWK=
NCI-H1770M2GxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2P6TGlEPTB;MkiuN|U3PiBizszNM3\OPHNCVkeHUh?=
BT-20NYTH[|lYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYfPXYVYUUN3ME2yPE4{Pjh3IDFOwG0>MVjTRW5ITVJ?
DBTRG-05MGMnvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGfs[5pKSzVyPUK4MlQ5OzhiIN88US=>NF7l[JNUSU6JRWK=
HPAF-IIMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFe5fGlKSzVyPUK4Mlc4QSBizszNNGezO2RUSU6JRWK=
SW837MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEPOUHJKSzVyPUK5MlM{QDViIN88US=>MnfpV2FPT0WU
647-VNVuwUGJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3zXZ2lEPTB;MkmuO|AxOyBizszNNV61OpBwW0GQR1XS
J82NUPGeIpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mlf3TWM2OD1{OT64NFE{KCEQvF2=NUfiPWp[W0GQR1XS
MC116NYfNfIJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYnJR|UxRTNyLkC3N|MhKM7:TR?=MnX4V2FPT0WU
NCI-H69NXjMfFVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXnJR|UxRTNyLk[wPVMhKM7:TR?=M1Szc3NCVkeHUh?=
NB6NF\n[Y5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVTjdHgzUUN3ME2zNU4{PjJ7IDFOwG0>NVflSoE1W0GQR1XS
CAL-120MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmC2TWM2OD1|Mj60N|E4KCEQvF2=NUSzcYV7W0GQR1XS
U-87-MGMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml\WTWM2OD1|Mz6wNlUyKCEQvF2=MkjhV2FPT0WU
NCI-H1304NF36OppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUG1XWtKUUN3ME2zN{4xOzV2IDFOwG0>NUD0NFAzW0GQR1XS
YH-13M3HGbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRTN|LkK1N|UhKM7:TR?=Mn7nV2FPT0WU
RMG-INVfPS25LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3LybmlEPTB;M{OuOFI5PSBizszNMkK5V2FPT0WU
LU-65NY\ZcHlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnz2TWM2OD1|ND6xOFA5KCEQvF2=NID1XFVUSU6JRWK=
GB-1MlrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUfFRVVmUUN3ME2zOU4xPzJ7IDFOwG0>NETldpZUSU6JRWK=
DU-4475M4XWfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUDqNItoUUN3ME2zOU4yPTV|IDFOwG0>M4rWV3NCVkeHUh?=
SBC-5MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3zRTWlEPTB;M{[uOVkxOiBizszNMlLqV2FPT0WU
OE33MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkXYTWM2OD1|Nz63OVc4KCEQvF2=NUHB[lBnW0GQR1XS
C8166NYn5ZnNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{j4SGlEPTB;M{iuOVI3PyBizszNNHy1WoVUSU6JRWK=
COLO-684NX7NWZRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml\iTWM2OD1|OD63OFI5KCEQvF2=MWLTRW5ITVJ?
NCI-H1155MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEXnVYZKSzVyPUO5MlA1PzFiIN88US=>M{L5eHNCVkeHUh?=
ATN-1M4ThS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWTEZYNDUUN3ME2zPU44Pzl{IDFOwG0>MkHEV2FPT0WU
KARPAS-299MnnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmL0TWM2OD1|OT64N|khKM7:TR?=MnzoV2FPT0WU
KNS-81-FDMlHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV\JR|UxRTRyLkO2NFQhKM7:TR?=NF[4fpJUSU6JRWK=
NCI-H1563M3jafmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1jLdWlEPTB;NEGuOVA{QSBizszNNFrvOZVUSU6JRWK=
NB14NGLBOGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYLZdohLUUN3ME20Nk44OjZ|IDFOwG0>Mn3NV2FPT0WU
COLO-800NVjXcllWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHvYUHFKSzVyPUSyMlg2OTdiIN88US=>Mo\IV2FPT0WU
MS-1NV3GeVJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF\BVZdKSzVyPUSzMlA1QDNiIN88US=>MXTTRW5ITVJ?
OVCAR-8MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF:1VnBKSzVyPUSzMlY5ODliIN88US=>NHTFdlBUSU6JRWK=
SK-PN-DWMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXTJR|UxRTR|Lki3O|YhKM7:TR?=NWjkPXF{W0GQR1XS
G-402MmHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEf3d4dKSzVyPUSzMlkxODZiIN88US=>NEDRdWRUSU6JRWK=
NCI-H2291NF24OIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnGwTWM2OD12ND64NFE4KCEQvF2=MWXTRW5ITVJ?
PC-3NF\YO3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIDZT3FKSzVyPUS1MlgxOjNiIN88US=>NX7qPHppW0GQR1XS
NCI-H1581MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1rROWlEPTB;NEWuPVg5QSBizszNMYfTRW5ITVJ?
SW1116MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MU\JR|UxRTR5LkCxPFIhKM7:TR?=NE\1OoFUSU6JRWK=
ZR-75-30NH7qdY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2HyUGlEPTB;NEeuNFI{QSBizszNM1qzN3NCVkeHUh?=
OCI-AML2NFjoe5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoqwTWM2OD12Nz6wPVE5KCEQvF2=M4XXTXNCVkeHUh?=
MDA-MB-231NXrudZBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXi4OnN3UUN3ME20O{43OjR7IDFOwG0>NEHsS|dUSU6JRWK=
ES3NELtZWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1;VZmlEPTB;NEiuN|UzQSBizszNM1rFdnNCVkeHUh?=
NCI-H630NGPhbpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1;tSmlEPTB;NEmuNVc1OiBizszNMYrTRW5ITVJ?
OE19M4riWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHfXPFFKSzVyPUS5MlI6ODJiIN88US=>NF3JZlZUSU6JRWK=
NCI-H1573NFrjSnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoHaTWM2OD12OT62PFYyKCEQvF2=MWXTRW5ITVJ?
EW-1MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVXJR|UxRTR7LkmwPFQhKM7:TR?=NIn0VZRUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Bosutinib (60 mg/kg/day) is active against Src-transformed fibroblasts xenografts and HT29 xenografts in nude mice with T/C of 18% and 30%, respectively. [1] Oral administration of Bosutinib for 5 days significantly suppresses K562 tumor growth in mice in a dose-dependent manner, with the large tumors eradicated at dose of 100 mg/kg and tumor free at 150 mg/kg without overt toxicity. [2] As being inactive against Colo205 xenografts in nude mice at 50 mg/kg twice daily, Bosutinib dosing at 75 mg/kg twice daily is necessary against Colo205 xenografts, and increasing the dose of Bosutinib has no additional benefit, in contrast to the significant dose-dependent ability against HT29 xenografts. [4]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

The Src and Abl kinase assays The Src kinase activity is measured in an ELISA format. Src (3 units/reaction), reaction buffer (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 0.1 mM EGTA, 0.5 mM Na3VO4) and cdc2 substrate peptide are added to various concentration of Bosutinib and incubated at 30 °C for 10 minutes. The reaction is started by the addition of ATP to a final concentration of 100 μM, incubated at 30 °C for 1 hour and stopped by addition of EDTA. Instructions from the manufacturer are followed for subsequent steps. The Abl kinase assay is performed in a DELFIA solid phase europium-based detection assay format. Biotinylated peptide (2 μM) is bound to streptavidin-coated microtitration plates for 1.5 hours in 1 mg/mL ovalbumin in PBS. The plates are washed for 1 hour with PBS/0.1% Tween 80, followed by a PBS wash. The kinase reaction is incubated for 1 hour at 30°C. Abl kinase (10 units) is mixed with 50 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 80 μM EGTA, 100 μM ATP, 0.5 mM Na3VO4, 1% DMSO, 1 mM HEPES (pH 7.0), 200 μg/mL ovalbumin and various concentration of Bosutinib. The reaction is stopped with EDTA at a final concentration of 50 mM. The reaction is monitored with Eu-labeled phosphotyrosine antibody and DELFIA enhancement solution.

Cell Assay:

[2]

Cell lines Abl-MLV, Rat 2, KU812, K562, and MEG-01 cells
Concentrations Dissolved in DMSO, final concentrations ~1 μM
Incubation Time 72 hours
Method

Cells are exposed to various concentrations of Bosutinib for 72 hours. Anchorage-independent proliferation of Abl-MLV-transformed fibroblasts is measured in 96-well ultra-low binding plates treated with Sigmacote to block residual cell attachment. Cell proliferation is measured with MTS or Cell-Glo. For the determination of cell cycle or cell death, cells are prepared for FACS analysis in the CycleTest Plus DNA reagent kit and analyzed on a fluorescence-activated cell sorter flow cytometer.

Animal Study:

[2]

Animal Models Nude female mice injected with K562 cells
Formulation Suspended in 0.5% methocel/0.4% Tween 80
Dosages ~150 mg/kg/day
Administration Oral gavage

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Boschelli DH, et al. J Med Chem, 2001, 44(23), 3965-3977.

[2] Golas JM, et al. Cancer Res, 2003, 63(2), 375-381.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-01-10)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02638467 Recruiting Leukemia|Myelogenous|Chronic|BCR-ABL Positive University of Milano Bicocca|IRCCS San Raffaele November 2015 Phase 2
NCT02546375 Recruiting Chronic Myeloid Leukaemia Pfizer|pH Associates October 2015 --
NCT02501330 Active, not recruiting Chronic Myelogenous Leukemia Pfizer July 2015 --
NCT02445742 Recruiting Chronic Myeloblastic Leukaemia PETHEMA Foundation May 2015 Phase 2
NCT02311998 Recruiting Leukemia M.D. Anderson Cancer Center|Pfizer April 2015 Phase 1|Phase 2

view more

Chemical Information

Download Bosutinib (SKI-606) SDF
Molecular Weight (MW) 530.45
Formula

C26H29Cl2N5O3

CAS No. 380843-75-4
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 100 mg/mL (188.51 mM)
Ethanol 2 mg/mL (3.77 mM)
Water <1 mg/mL (<1 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 4-(2,4-dichloro-5-methoxyphenylamino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Customer Product Validation (3)


Click to enlarge
Rating
Source J Virol 2011 85, 2296–2303. Bosutinib (SKI-606) purchased from Selleck
Method Endothelial cell permeability assay
Cell Lines Human endothelial cells
Concentrations 0-10 μM
Incubation Time 15-60 min
Results Figure C defines concentrations of kinase inhibitors which block ANDV-induced EC permeability approximately 50% (IC50s). IC50s of bosutinib are 100 nM and 10 μM. we next assessed the abilities of bosutinib to block ANDV-induced permeability at its IC50s from 15 to 60 min after VEGF addition, we find that bosutinib inhibited ANDV-induced permeability up to 40 to 50% but only at IC50s of 10 μM(Figure D).

Click to enlarge
Rating
Source J Biol Chem 2010 285, 7977–7985. Bosutinib (SKI-606) purchased from Selleck
Method Western blot
Cell Lines Mouse sperm
Concentrations 0-50 μM
Incubation Time 60 min
Results In the case of SKI606, a sharp inhibitory effect was observed at 50 μM.

Click to enlarge
Rating
Source Dr. Pablo E.Visconti from University of Massachusetts. Bosutinib (SKI-606) purchased from Selleck
Method Western blot
Cell Lines sperm
Concentrations 50 μΜ
Incubation Time
Results PKA and tyrosine phosphorylation was rescue by Ser/Thr phosphatase inhibitors SKI-606 and SU6656.

Product Use Citation (11)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Src Products

  • Dasatinib Monohydrate

    Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.

  • SU6656

    SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.

  • PX-478 2HCl

    PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.

  • Saracatinib (AZD0530)

    Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Phase 2/3.

    Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

  • Dasatinib

    Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

  • KX2-391

    KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 2.

  • PP1

    PP1 is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.

  • PP2

    PP2, a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM in cell-free assays, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.

  • WH-4-023

    WH-4-023 is a potent and orally active Lck/Src inhibitor with IC50 of 2 nM and 6 nM in cell-free assays, respectively.

  • Ibrutinib (PCI-32765)

    Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.

Recently Viewed Items

Tags: buy Bosutinib (SKI-606) | Bosutinib (SKI-606) ic50 | Bosutinib (SKI-606) price | Bosutinib (SKI-606) cost | Bosutinib (SKI-606) solubility dmso | Bosutinib (SKI-606) purchase | Bosutinib (SKI-606) manufacturer | Bosutinib (SKI-606) research buy | Bosutinib (SKI-606) order | Bosutinib (SKI-606) mouse | Bosutinib (SKI-606) chemical structure | Bosutinib (SKI-606) mw | Bosutinib (SKI-606) molecular weight | Bosutinib (SKI-606) datasheet | Bosutinib (SKI-606) supplier | Bosutinib (SKI-606) in vitro | Bosutinib (SKI-606) cell line | Bosutinib (SKI-606) concentration | Bosutinib (SKI-606) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us